EU green light to IntraBio’s AQNEURSA for rare neurological disease Niemann-Pick Type C
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
The approval is grounded in data from a Phase III randomized, double-blind, placebo-controlled, crossover study in NPC patients
Company to launch product after the expiry of semaglutide patent in India
A dedicated Life Sciences Innovation Fund, scalable up to Rs. 1,000 crore, will catalyze early- and growth-stage innovation, support deep-tech ventures – particularly biotherapeutics
The RMAT designation accelerates the development of regenerative medicine therapies for serious or life-threatening diseases
The Phase 1 single and multiple ascending dose study is set to begin dosing in early Q1 2026
The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing
The registrations grant Neurizon exclusive rights to use and defend its brand across its core operating regions
Stevens succeeds Milton Boyer, who has stepped down as CEO but will remain closely involved with the business as an independent member of Kindeva’s Board of Directors
ALTO-207 combines pramipexole, a dopamine D3-preferring D3/D2 agonist approved for Parkinson’s disease
Berendsen brings over 15 years of financial leadership experience spanning professional services and international trade
Subscribe To Our Newsletter & Stay Updated